Shares of SpringWorks Therapeutics, Inc. SWTX have rallied 45.8% in the past year against the industry’s decline of 6.7%. Earlier this month, the company completed the new drug application (NDA) ...

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new ...

Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation ...

SpringWorks Therapeutics received FDA approval for its oral gamma secretase inhibitor Ogsiveo, for the treatment of adult patients with desmoid tumors. The approval is based on positive results from ...

– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add ...

Presented positive topline data from the pivotal Phase 2b ReNeu trial evaluating mirdametinib, an investigational oral MEK inhibitor, in pediatric and adult patients with neurofibromatosis type ...

SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biotechnology company with a market capitalization of $2.66 billion focused on developing targeted therapies for patients with severe rare diseases and ...

STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The ...

Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancers Financials include a $13 million upfront payment and potential for ...

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European ...